Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

FDA-approved PET agent helps solve 87% of diagnostic breast cancer dilemmas

In 93% of solved cases, experts based their decisions solely on 18F-FES PET scan results.

Thumbnail

‘A troublesome trend’: Top imaging groups slam insurer-directed test substitution policies

Advocates say payers' push for single first-line imaging tests for all patients isn't backed by evidence and may cause harm.

Thumbnail

Top medical groups release new appropriate use criteria for PSMA-PET imaging

SNMMI is among the many organizations that collaborated on the updated guidance for imaging prostate cancer.

Thumbnail

Amyloid PET pinpoints ‘tipping point’ for developing Alzheimer’s dementia

Washington University in St. Louis experts say they can estimate how far dementia has progressed and how much time is left before cognitive impairment sets in.

‘Practice changing’: New research underscores clinical benefits of PSMA-PET for prostate cancer

California nuclear medicine experts said the technology will ultimately become part of routine staging for the disease, publishing their study findings in JAMA Oncology.

Thumbnail

National cancer network adds PSMA-PET agents to new prostate imaging guidelines

National Comprehensive Cancer Network recommendations are widely recognized by providers and payers as the standard for clinical policy in oncology.

Thumbnail

New PET imaging agent alters prostate cancer plan for more than 40% of patients

Lantheus recently presented early results from the OSPREY trial during the American Urological Association's virtual meeting.

Hybrid PET/CT early after treatment guides crucial decisions for many liver cancer patients

Follow-up imaging 4-8 weeks after transarterial radioembolization predicted six-month treatment response and overall survival.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.